REGENXBIO Inc.
RGNX
$12.50
$0.292.38%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 91.30% | 74.95% | 80.70% | -7.66% | -15.14% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 91.30% | 74.95% | 80.70% | -7.66% | -15.14% |
| Cost of Revenue | -3.83% | -3.29% | -8.93% | -9.15% | -10.27% |
| Gross Profit | 52.46% | 45.76% | 53.04% | 9.92% | 7.56% |
| SG&A Expenses | 0.78% | -4.97% | -11.71% | -18.42% | -17.30% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 538.67% | 179.28% | 176.97% | 117.88% | 101.03% |
| Total Operating Expenses | -2.52% | -3.50% | -9.43% | -11.31% | -8.33% |
| Operating Income | 35.47% | 32.25% | 39.49% | 12.55% | 5.66% |
| Income Before Tax | 25.55% | 27.22% | 39.42% | 13.86% | 8.30% |
| Income Tax Expenses | -- | -- | -- | -- | -253.49% |
| Earnings from Continuing Operations | 25.50% | 27.17% | 39.38% | 13.81% | 8.34% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 25.50% | 27.17% | 39.38% | 13.81% | 8.34% |
| EBIT | 35.47% | 32.25% | 39.49% | 12.55% | 5.66% |
| EBITDA | 37.75% | 34.19% | 41.76% | 12.98% | 5.83% |
| EPS Basic | 31.22% | 34.76% | 47.12% | 23.49% | 15.84% |
| Normalized Basic EPS | 29.44% | 33.15% | 45.95% | 23.22% | 15.52% |
| EPS Diluted | 31.22% | 34.79% | 47.18% | 23.57% | 15.99% |
| Normalized Diluted EPS | 29.44% | 33.15% | 45.95% | 23.22% | 15.52% |
| Average Basic Shares Outstanding | 7.47% | 10.98% | 14.91% | 13.19% | 9.71% |
| Average Diluted Shares Outstanding | 7.50% | 11.02% | 14.95% | 13.19% | 9.71% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |